Recursion Pharmaceuticals Drops: Clinical Trials in Focus

miércoles, 4 de junio de 2025, 5:46 pm ET1 min de lectura
RXRX--
Recursion Pharmaceuticals, Inc. surged -1.22% in after-hours trading, with the company having multiple clinical-stage projects, including high-potential projects in the fields of oncologyTOI-- and rare diseases. The company has built a full-stack platform that leverages various biological, chemical, and patient-centered proprietary datasets to industrialize the drug discovery process.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios